Literature DB >> 30094712

A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.

Sanjoy Ketan Paul1,2, Jason A Roberts3,4,5, Jeffrey Lipman3,4, Renae Deans3, Mayukh Samanta6.   

Abstract

BACKGROUND AND AIM: Current approaches to antibiotic dose determination in critically ill patients requiring renal replacement therapy are primarily based on the assessment of highly heterogeneous data from small number of patients. The standard modelling approaches limit the scope of constructing robust confidence boundaries of the distribution of pharmacokinetics (PK) parameters, especially when the evaluation of possible association of demographic and clinical factors at different levels of the distribution of drug clearance is of interest. Commonly used compartmental models generally construct the inferences through a linear or non-linear mean regression, which is inadequate when the distribution is skewed, multi-modal or effected by atypical observation. In this study, we discuss the statistical challenges in robust estimation of the confidence boundaries of the PK parameters in the presence of highly heterogenous patient characteristics.
METHODS: A novel stepwise approach to evaluate the confidence boundaries of PK parameters is proposed by combining PK modelling with mixed-effects quantile regression (MEQR) methods.
RESULTS: This method allows the assessment demographic and clinical factors' effects at any arbitrary quantiles of the outcome of interest, without restricting assumptions on the distributions. The MEQR approach allows us to investigate if the levels of association of the covariates are different at low, medium or high concentration.
CONCLUSIONS: This methodological assessment is deemed as a background initial approach to support the development of a class of statistical algorithm in constructing robust confidence intervals of PK parameters which can be used for developing an optimised antibiotic dosing guideline for critically ill patients requiring renal replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30094712     DOI: 10.1007/s40262-018-0690-1

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  38 in total

1.  Antibiotic Dosing In Critically Ill Patients Receiving Renal Replacement Therapy.

Authors:  Fekade Bruck Sime; Jason A Roberts
Journal:  Expert Rev Clin Pharmacol       Date:  2016-01-29       Impact factor: 5.045

2.  Quantile regression-opportunities and challenges from a user's perspective.

Authors:  Andreas Beyerlein
Journal:  Am J Epidemiol       Date:  2014-07-02       Impact factor: 4.897

3.  Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.

Authors:  T F Ververs; A van Dijk; S A Vinks; P J Blankestijn; J F Savelkoul; J Meulenbelt; F T Boereboom
Journal:  Crit Care Med       Date:  2000-10       Impact factor: 7.598

Review 4.  Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success.

Authors:  Nimish Patel; Marc H Scheetz; George L Drusano; Thomas P Lodise
Journal:  J Antimicrob Chemother       Date:  2010-08-24       Impact factor: 5.790

5.  Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.

Authors:  L J Giles; A C Jennings; A H Thomson; G Creed; R J Beale; A McLuckie
Journal:  Crit Care Med       Date:  2000-03       Impact factor: 7.598

6.  Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.

Authors:  Darren M Roberts; Jason A Roberts; Michael S Roberts; Xin Liu; Priya Nair; Louise Cole; Jeffrey Lipman; Rinaldo Bellomo
Journal:  Crit Care Med       Date:  2012-05       Impact factor: 7.598

7.  Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.

Authors:  H-S Lim; Y P Chong; Y-H Noh; J-A Jung; Y S Kim
Journal:  J Clin Pharm Ther       Date:  2014-01-16       Impact factor: 2.512

8.  Pharmacokinetics of ciprofloxacin and vancomycin in patients with acute renal failure treated by continuous haemodialysis.

Authors:  S P Davies; B S Azadian; W J Kox; E A Brown
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

9.  A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients.

Authors:  P E Marik; J Lipman; S Kobilski; J Scribante
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.